{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:38:56Z","timestamp":1786653536990,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Chronic pain management continues to challenge clinicians due to limitations in efficacy and tolerability of current pharmacological therapies. Suzetrigine, a first-in-class selective sodium channel blocker, has emerged as a promising agent for the treatment of neuropathic and chronic pain syndromes. Preclinical and clinical data highlight suzetrigine\u2019s unique sodium channel selectivity, reduced central nervous system side effects, and encouraging efficacy signals in neuropathic pain, trigeminal neuralgia, and refractory pain states. Early-phase trials report favorable safety and tolerability compared to conventional sodium channel blockers. Suzetrigine represents a promising new analgesic agent with a novel mechanism of action. Further Phase 3 studies are warranted to establish its role in pain medicine.<\/jats:p>","DOI":"10.4103\/ijp.ijp_854_25","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:02:29Z","timestamp":1777575749000},"page":"272-275","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Suzetrigine: A promising analgesic targeting voltage-gated sodium channel"],"prefix":"10.4103","volume":"58","author":[{"given":"Samarjit","family":"Dey","sequence":"first","affiliation":[{"name":"Department of Anaesthesiology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. V.","family":"Eeshwar","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamshidhar","family":"Chamala","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunit Kumar","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"R1-20260501","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/pme.12751","article-title":"The incidence and severity of postoperative pain following inpatient surgery","volume":"16","author":"Buvanendran","year":"2015","journal-title":"Pain Med"},{"key":"R2-20260501","first-page":"389","article-title":"The NaV1.7 sodium channel: From molecule to man","volume":"11","author":"Dib-Hajj","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"R3-20260501","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature05413","article-title":"An SCN9A channelopathy causes congenital inability to experience pain","volume":"444","author":"Cox","year":"2006","journal-title":"Nature"},{"key":"R4-20260501","first-page":"1404","article-title":"Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7","volume":"86","author":"Minett","year":"2015","journal-title":"Neuron"},{"key":"R5-20260501","first-page":"2889","article-title":"Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief","volume":"173","author":"Emery","year":"2016","journal-title":"Br J Pharmacol"},{"key":"R6-20260501","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/d41573-019-00065-0","article-title":"Nav1.7 withholds its pain potential","volume":"18","author":"Kingwell","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"R7-20260501","first-page":"1230","article-title":"Gain of function NaV1.7 mutations in idiopathic small fiber neuropathy","volume":"135","author":"Faber","year":"2012","journal-title":"Brain"},{"key":"R8-20260501","first-page":"773","article-title":"Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia","volume":"127","author":"Yang","year":"2004","journal-title":"Brain"},{"key":"R9-20260501","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1474-4422(14)70024-9","article-title":"Painful and painless channelopathies","volume":"13","author":"Bennett","year":"2014","journal-title":"Lancet Neurol"},{"key":"R10-20260501","first-page":"e96054","article-title":"Clinical Efficacy and Safety Profile of Suzetrigine: A Novel Non-opioid Analgesic Targeting NaV1.8 Sodium Channel","volume":"17","author":"Rejeev","year":"2025","journal-title":"Cureus"},{"key":"R11-20260501","first-page":"587","article-title":"Multimodal strategies to improve surgical outcome","volume":"127","author":"Kehlet","year":"2021","journal-title":"Br J Anaesth"},{"key":"R12-20260501","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1744-8069-7-32","article-title":"Nav1.7 is the predominant sodium channel in rodent olfactory sensory neurons","volume":"7","author":"Ahn","year":"2011","journal-title":"Mol Pain"},{"key":"R13-20260501","first-page":"898","article-title":"Sodium channel blockers as potential therapeutic targets for inflammatory pain","volume":"18","author":"Imam","year":"2020","journal-title":"Curr Neuropharmacol"},{"issue":"Suppl 1","key":"R14-20260501","first-page":"S66","article-title":"Voltage gated sodium channel blockers for the treatment of chronic pain","volume":"162","author":"Rahman","year":"2021","journal-title":"Pain"},{"key":"R15-20260501","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(17)30005-4","article-title":"Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: A randomized, double-blind, placebo-controlled, phase 2a study","volume":"16","author":"Zakrzewska","year":"2017","journal-title":"Lancet Neurol"},{"key":"R16-20260501","first-page":"106","article-title":"Sodium channel blockers in neuropathic pain","volume":"6","author":"Kalso","year":"2012","journal-title":"Curr Opin Support Palliat Care"},{"key":"R17-20260501","first-page":"3357","article-title":"Pharmacological characterization of a novel selective Nav1.7 inhibitor","volume":"14","author":"Harty","year":"2021","journal-title":"J Pain Res"},{"key":"R18-20260501","first-page":"1026","article-title":"Population pharmacokinetics of VX-548 in healthy volunteers and pain patients","volume":"109","author":"Paillard","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R19-20260501","first-page":"25","article-title":"VX-548 in postoperative pain after bunionectomy: A randomized, placebo- and active-controlled phase 2 study","volume":"39","author":"Hale","year":"2023","journal-title":"Clin J Pain"},{"key":"R21-20260501","first-page":"1446","article-title":"Evaluating cognitive and respiratory effects of novel analgesics","volume":"21","author":"Zeltser","year":"2020","journal-title":"Pain Med"},{"key":"R22-20260501","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamasurg.2016.4952","article-title":"Enhanced recovery after surgery: A review","volume":"152","author":"Ljungqvist","year":"2017","journal-title":"JAMA Surg"},{"key":"R23-20260501","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1097\/CCM.0000000000003299","article-title":"Clinical practice guidelines for the prevention and management of pain, agitation\/sedation, delirium in the ICU","volume":"46","author":"Devlin","year":"2018","journal-title":"Crit Care Med"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_854_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:38:58Z","timestamp":1786649938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_854_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_854_25","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-08-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}